Core Insights - Tesla's new car registrations in France more than tripled in March, indicating a strong recovery in sales in Europe [1][3] - The company registered 9,569 new cars in France in March, a 203.10% increase from the same month in 2025, and just shy of the all-time high of 9,572 vehicles registered in December 2023 [4] - First-quarter registrations in France were up 108% year-over-year, totaling 13,945 cars [4] Market Context - Tesla lost nearly half of its share in the European market last year due to increased competition, particularly from Chinese brands, and a lack of new models [2] - The introduction of new, cheaper versions of the Model Y and Model 3 in late 2025 has contributed to the recent growth in European registrations [3]

Investment Rating - The report maintains a BUY rating for Giant Biogene, expecting earnings pressure to ease progressively through 2026E and injectables to drive medium- to long-term growth [1][8]. Core Views - Giant Biogene reported revenue of RMB5,519 million in 2025, a slight decline of 0.4% YoY, and an attributable net profit of RMB1,915 million, down 7.2% YoY, which was in line with expectations given external headwinds and competition [1][2]. - The gross margin decreased by 1.8 percentage points YoY to 80.3%, primarily due to changes in product mix [1]. - For 2026E, sales growth is expected to recover gradually, driven by stronger brand promotion for KOMFYMED and Collgene, an expanded product portfolio, and the commercialization of newly approved Class III injectables [1][8]. - The target price has been lowered to HK$38.70 from HK$53.89, reflecting a revised revenue and net profit CAGR forecast from 18%/17% to 11%/8% for 2025-28E due to intensified competition [1][3]. Financial Summary - Revenue projections for FY26E, FY27E, and FY28E are RMB6,073 million, RMB6,809 million, and RMB7,522 million respectively, with YoY growth rates of 10.1%, 12.1%, and 10.5% [2][12]. - Attributable net profit is expected to be RMB1,964 million in FY26E, RMB2,201 million in FY27E, and RMB2,432 million in FY28E, with corresponding YoY growth rates of 2.6%, 12.1%, and 10.5% [2][12]. - The P/E ratio is projected to be 14.7x for FY26E, 13.1x for FY27E, and 11.9x for FY28E [2][12]. Product and Market Insights - KOMFYMED's revenue was RMB4,470 million in 2025, down 1.6% YoY, while Collgene grew by 9.2% YoY to RMB918 million [1][8]. - The company plans to launch several key products in 2026E, including KOMFYMED Focus Cream 2.0 and new additions to the Focus and Regular series, to support recovery [1][8]. - Offline direct sales increased by 32% YoY to RMB225 million in 2025, contributing 4.1% to total revenue, driven by the expansion of KOMFYMED offline stores [1][8]. Regulatory and Commercialization Developments - Giant Biogene received NMPA approvals for two Class III injectables in late 2025 and early 2026, with commercialization expected to begin in 2Q26E [1][8]. - The company is preparing for commercialization through market research and distributor selection, leveraging its nationwide sales network [1][8].

Group 1 - Kering reported a slightly smaller-than-expected drop in fourth-quarter sales [1] - The new CEO, Luca de Meo, is working to stabilize the company [1]

Core Insights - Levi Strauss & Co. is experiencing a sales recovery and is projected to reach new highs by 2026, driven by a strategic transformation focusing on direct-to-consumer, omnichannel, and e-commerce initiatives [3][4] - The company maintains a strong balance sheet, generates healthy cash flow, and is committed to returning capital to shareholders, making it appealing for income-oriented investors [3][5] Financial Performance - In the latest quarter, Levi's core business grew by 6.9%, outperforming market expectations, with Asia leading growth at 12% [8][9] - The company reported adjusted earnings of $0.34, a 3% year-over-year increase, significantly exceeding expectations [9][10] Capital Return Strategy - Levi Strauss has initiated an accelerated share repurchase program worth approximately 1.2% of its market cap, expected to be completed by the fiscal year's end [4] - The annualized dividend payment for FY2025 is projected at 56 cents, representing about 41% of the earnings outlook, supported by strong cash flow [5][6] Market Outlook - Analysts are bullish on Levi Strauss, with a 12-month stock price forecast of $26.36, indicating a potential upside of 22.21% [11] - Institutional investors have been consistently buying shares, accumulating over $2 for every $1 sold, indicating strong market support [12] Technical Analysis - Following the recent earnings release, the stock experienced a bearish trend, selling off by more than 8% in pre-market trading, creating a potential buying opportunity [12][13] - A strong support target is identified near $21.70, which may trigger a rebound if the stock price declines further [13]

Core Viewpoint - HSBC has upgraded Nike's stock rating to 'Buy' from 'Hold' and increased the price target to $80 from $60, citing evidence of sales recovery and margin improvement [1] Group 1: Upgrade Factors - The new management team under CEO Elliott Hill is focusing on quality over quick fixes, which is expected to benefit Nike in the long term [2] - The repositioning of the digital channel as a full-price channel is highlighted as a positive change [2] - After two quarters of inventory clean-up, the brand assortment is expected to be current and exciting, despite challenges with the Dunk line [2] Group 2: Financial Performance - Nike's stock surged 12% in after-hours trading following the earnings call, despite mixed results [3] - The company reported earnings per share of 14 cents, slightly above estimates, while sales declined 12% to $11.1 billion [3] - Net income fell 86% to $211 million from $1.5 billion in the previous year [3] Group 3: Challenges and Outlook - Nike faces headwinds from new tariffs on Chinese goods, expecting a $1 billion impact in fiscal 2026 [4] - Currently, 16% of Nike's supply chain runs through China, with plans to reduce this to high single digits by next summer as part of the 'Win Now' strategy [4] - HSBC's price target of $80 indicates a 28% upside from Nike's current trading price of $62.54, despite a year-to-date decline of 17.35% prior to the recent rally [4]

Core Viewpoint - Abbott Laboratories is experiencing strong sales recovery in its Nutrition business, particularly driven by Ensure, and is well-positioned for growth in emerging markets and its Diabetes Care segment through the FreeStyle Libre system [1][5][6] Group 1: Sales Performance - Abbott's shares have increased by 19.6% over the past year, outperforming the industry growth of 9.1% and the S&P 500's increase of 5.4% [2] - In the fourth quarter of 2024, Abbott's Diabetes Care sales exceeded $1.8 billion, reflecting a 23% growth, while full-year sales reached approximately $6.5 billion, up 22% from 2023 [7] - The Nutrition business reported 7.1% organic growth in the fourth quarter of 2024, with Adult Nutrition growing by 11.4% [9] Group 2: Business Segments - The EPD (Established Pharmaceutical Division) is set for sustainable growth, with a five-year compound annual growth rate (CAGR) of 8% [3] - EPD sales in the fourth quarter of 2024 increased by 8.5% organically, with balanced growth across various therapeutic areas [4] - The FreeStyle Libre system has achieved global leadership in continuous glucose monitoring for both Type 1 and Type 2 diabetes users [5] Group 3: Market Dynamics - Abbott has gained momentum in the Diabetes Care segment with recent FDA approvals for new over-the-counter CGM systems, expanding its market reach [6] - The Nutrition business is expanding due to strong global demand for adult nutrition products, despite some softness in pediatric product markets [8] - Foreign exchange fluctuations have negatively impacted Abbott's sales, with a 1.4% unfavorable year-over-year effect noted in the fourth quarter of 2024 [10] Group 4: Financial Estimates - The Zacks Consensus Estimate for Abbott's 2025 earnings per share remains at $5.15, while revenues are projected to rise by 5.7% to $44.35 billion [11]